Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19

BACKGROUND AND OBJECTIVES: The use of COVID-19 convalescent plasma (CCP) has been approved by the FDA. We assessed the outcome of patients with moderate and severe COVID-19 following convalescent plasma therapy and the association with variables such as antibody titer in CCP units and transfusion ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Fazeli, Alieh, Sharifi, Shahin, Behdad, Fatemeh, Okati, Shamsi, Esmaielifar, Gilda, Jelveh, Nooshin, Eshghi, Peyman, Mohammadi, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612443/
https://www.ncbi.nlm.nih.gov/pubmed/34836825
http://dx.doi.org/10.1016/j.transci.2021.103321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612443/
https://www.ncbi.nlm.nih.gov/pubmed/34836825
http://dx.doi.org/10.1016/j.transci.2021.103321

Ejemplares similares